Skip to main content
Erschienen in: Annals of Nuclear Medicine 10/2018

17.08.2018 | Original Article

Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer

verfasst von: Yukako Nakanishi, Kazuhiro Kitajima, Yusuke Yamada, Takahiko Hashimoto, Toru Suzuki, Shuken Go, Akihiro Kanematsu, Michio Nojima, Koichiro Yamakado, Shingo Yamamoto

Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare findings obtained with 11C-choline and FDG PET/CT scanning for renal cell carcinoma staging and restaging.

Materials and methods

Twenty-eight renal cell carcinoma patients whose histological subtype was clear cell type in 26 and papillary type in 2, while Fuhrman nuclear grade was G1,2 in 16 and G3,4 in 12, underwent both 11C-choline and FDG PET/CT examinations before (n = 10) and/or after (n = 18) treatment, then those scanning modalities were compared in regard to patient- and lesion-based diagnostic performance using 5 grading scores. Final diagnosis in each case was obtained based on histopathology, conventional radiological imaging, and clinical follow-up findings. The differences between 11C-choline and FDG PET/CT findings were evaluated using receiver-operating-characteristic (ROC) analysis and a McNemar test.

Results

Patient-based sensitivity, specificity, positive predictive, negative predictive, accuracy, and area under the ROC curve (AUC) values for 11C-choline PET/CT for staging and restaging were 88.0% (22/25), 66.7% (2/3), 95.7% (22/23), 40.0% (2/5), 85.7% (24/28), and 0.887, respectively, while those for FDG-PET/CT were 56.0% (14/25), 66.7% (2/3), 93.3% (14/15), 15.4% (2/13), 57.1% (16/28), and 0.647, respectively. Sensitivity, accuracy, and AUC were significantly different (p = 0.013, p = 0.013, p = 0.012, respectively). Among the 120 lesions, those with kidney, lung, lymph node, bone, pancreas, venous tumor thrombosis, adrenal gland, liver, or skin localization numbered 15, 64, 16, 13, 4, 3, 2, 2, and 1, respectively. For all 120 lesions, 75 (62.5%) and 47 (39.2%) were detected by 11C-choline and FDG PET/CT, respectively (p < 0.0001).

Conclusion

For staging and restaging of renal cell carcinoma patients, 11C-choline-PET/CT is significantly more useful than FDG-PET/CT.
Literatur
1.
Zurück zum Zitat Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. Guidelines on renal cell carcinoma. Eur Urol. 2015;67:913–24.CrossRef Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. Guidelines on renal cell carcinoma. Eur Urol. 2015;67:913–24.CrossRef
2.
Zurück zum Zitat Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):49–56.CrossRef Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):49–56.CrossRef
3.
Zurück zum Zitat Smaldone MC, Chen DY, Yu JQ, Plimack ER. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395–407.PubMedPubMedCentral Smaldone MC, Chen DY, Yu JQ, Plimack ER. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395–407.PubMedPubMedCentral
4.
Zurück zum Zitat Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, et al. FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging. 2015;15:15.CrossRef Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, et al. FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging. 2015;15:15.CrossRef
5.
Zurück zum Zitat Oyama N, Takahara N, Hasegawa Y, Tanase K, Miwa Y, Akino H, et al. Assessment of therapeutic effect of sunitinib by 11C-Acetate PET compared with FDG PET imaging in a patient with metastatic renal cell carcinoma. Nucl Med Mol Imaging. 2011;45:217–19.CrossRef Oyama N, Takahara N, Hasegawa Y, Tanase K, Miwa Y, Akino H, et al. Assessment of therapeutic effect of sunitinib by 11C-Acetate PET compared with FDG PET imaging in a patient with metastatic renal cell carcinoma. Nucl Med Mol Imaging. 2011;45:217–19.CrossRef
6.
Zurück zum Zitat Middendorp M, Maute L, Sauter B, Vogl TJ, Grünwald F. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441–6.CrossRef Middendorp M, Maute L, Sauter B, Vogl TJ, Grünwald F. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441–6.CrossRef
7.
Zurück zum Zitat Kitajima K, Fukushima K, Yamamoto S, Kato T, Odawara S, Takaki H, et al. 11C-Choline positive but 18F-FDG negative pancreatic metastasis from renal cell carcinoma on PET. Nagoya J Med Sci. 2017;79:273–7.PubMedPubMedCentral Kitajima K, Fukushima K, Yamamoto S, Kato T, Odawara S, Takaki H, et al. 11C-Choline positive but 18F-FDG negative pancreatic metastasis from renal cell carcinoma on PET. Nagoya J Med Sci. 2017;79:273–7.PubMedPubMedCentral
8.
Zurück zum Zitat Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, et al. Hypoxia in Renal Cancer Multicenter Group: metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med. 2011;52:1048–55.CrossRef Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, et al. Hypoxia in Renal Cancer Multicenter Group: metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med. 2011;52:1048–55.CrossRef
9.
Zurück zum Zitat Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F] FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434–8.CrossRef Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F] FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434–8.CrossRef
10.
Zurück zum Zitat Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61:372–8.CrossRef Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61:372–8.CrossRef
11.
Zurück zum Zitat Uchida T, Yamashita S. Molecular cloning, characterization, and expression in Escherichia coli of a cDNA encoding mammalian choline kinase. J Biol Chem. 1992;267:10156–62.PubMed Uchida T, Yamashita S. Molecular cloning, characterization, and expression in Escherichia coli of a cDNA encoding mammalian choline kinase. J Biol Chem. 1992;267:10156–62.PubMed
12.
Zurück zum Zitat Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology. Jpn J Radiol. 2016;34:470–85.CrossRef Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology. Jpn J Radiol. 2016;34:470–85.CrossRef
13.
Zurück zum Zitat Hara T, Yuasa M. Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot. 1999;50:531–3.CrossRef Hara T, Yuasa M. Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot. 1999;50:531–3.CrossRef
14.
Zurück zum Zitat Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29–35.CrossRef Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29–35.CrossRef
15.
Zurück zum Zitat Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:464–73.CrossRef Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:464–73.CrossRef
16.
Zurück zum Zitat Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–9.CrossRef Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–9.CrossRef
17.
Zurück zum Zitat Kumar R, Shandal V, Shamim SA, Jeph S, Singh H, Malhotra A. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010;31:844–50.PubMed Kumar R, Shandal V, Shamim SA, Jeph S, Singh H, Malhotra A. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010;31:844–50.PubMed
18.
Zurück zum Zitat Fuccio C, Ceci F, Castellucci P, Spinapolice EG, Palumbo R, D’Ambrosio D, et al. Restaging clear cell renal carcinoma with 18F-FDG PET/CT. Clin Nucl Med. 2014;39:e320-4.PubMed Fuccio C, Ceci F, Castellucci P, Spinapolice EG, Palumbo R, D’Ambrosio D, et al. Restaging clear cell renal carcinoma with 18F-FDG PET/CT. Clin Nucl Med. 2014;39:e320-4.PubMed
19.
Zurück zum Zitat Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38:156–63.CrossRef Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38:156–63.CrossRef
20.
Zurück zum Zitat Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDGPET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464–74.CrossRef Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDGPET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464–74.CrossRef
21.
Zurück zum Zitat Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15–8.CrossRef Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15–8.CrossRef
22.
Zurück zum Zitat Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30:1236–45.CrossRef Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30:1236–45.CrossRef
23.
Zurück zum Zitat Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995–4000.CrossRef Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995–4000.CrossRef
24.
Zurück zum Zitat Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S. Evaluation of renal cell carcinoma histological subtype and Fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol. 2017;27:4866–73.CrossRef Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S. Evaluation of renal cell carcinoma histological subtype and Fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol. 2017;27:4866–73.CrossRef
25.
Zurück zum Zitat Visentin M, Torozi A, Gai Z, Häusler S, Li C, Hiller C, et al. Fluorocholine transport mediated by the organic cation transporter 2 (OCT2, SLC22A2): implication for imaging of kidney tumors. Drug Metab Dispos. 2018;46:1129–36.CrossRef Visentin M, Torozi A, Gai Z, Häusler S, Li C, Hiller C, et al. Fluorocholine transport mediated by the organic cation transporter 2 (OCT2, SLC22A2): implication for imaging of kidney tumors. Drug Metab Dispos. 2018;46:1129–36.CrossRef
Metadaten
Titel
Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer
verfasst von
Yukako Nakanishi
Kazuhiro Kitajima
Yusuke Yamada
Takahiko Hashimoto
Toru Suzuki
Shuken Go
Akihiro Kanematsu
Michio Nojima
Koichiro Yamakado
Shingo Yamamoto
Publikationsdatum
17.08.2018
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 10/2018
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1287-3

Weitere Artikel der Ausgabe 10/2018

Annals of Nuclear Medicine 10/2018 Zur Ausgabe